Current News

Contact | Print version | PDF version | Send article | RSS feed

BAC and LFB Biotechnologies to Develop Custom Ligand for Purifying Recombinant Factor VIIa

30 May 2008 - BAC BV, the Bio Affinity Company, announced that it has entered into a collaboration with LFB Biotechnologies, a wholly owned subsidiary of LFB S.A., a biopharmaceutical company working in the highly specialized field of plasma-derived medicinal and biotech products. Working with LFB, BAC will discover and develop a custom CaptureSelect ligand for the purification of a recombinant Factor VIIa product - an essential protein for certain blood coagulation disorders - developed by LFB with GTC Biotherapeutics. The CaptureSelect ligand has the potential to obtain high purity in downstream processing while enhancing the cost reduction benefits of the transgenic expression system developed by LFB and GTC. LFB and GTC are producing Factor VIIa in the milk of animals that express this recombinant protein during lactation.
 
BAC has a proven reputation for the rapid discovery and development of customized ligands for a wide range of affinity applications from the purification of monoclonal antibodies and viruses, to plasma proteins. The CaptureSelect ligands are suitable and available for use at commercial biomanufacturing scale and for bench research.
 
"Our expertise in the custom design of affinity ligands makes BAC a great match for LFB in this project," commented Laurens Sierkstra, CEO of BAC. "Our technology platform enables us to produce ligands that are not only highly specific for the target protein, but will generate a very pure product in a single purification step. We are very much looking forward to working with LFB to develop a ligand for their recombinant Factor VIIa protein that will help to simplify and streamline the purification process."